146 related articles for article (PubMed ID: 28521171)
1. Review of phase I and II trials for Wilms' tumour - Can we optimise the search for novel agents?
Brok J; Pritchard-Jones K; Geller JI; Spreafico F
Eur J Cancer; 2017 Jul; 79():205-213. PubMed ID: 28521171
[TBL] [Abstract][Full Text] [Related]
2. Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting.
Brok J; Mavinkurve-Groothuis AMC; Drost J; Perotti D; Geller JI; Walz AL; Geoerger B; Pasqualini C; Verschuur A; Polanco A; Jones KP; van den Heuvel-Eibrink M; Graf N; Spreafico F
Eur J Cancer; 2021 Feb; 144():113-122. PubMed ID: 33341445
[TBL] [Abstract][Full Text] [Related]
3. A multi-Gaussian model for apparent diffusion coefficient histogram analysis of Wilms' tumour subtype and response to chemotherapy.
Hales PW; Olsen ØE; Sebire NJ; Pritchard-Jones K; Clark CA
NMR Biomed; 2015 Aug; 28(8):948-57. PubMed ID: 26058670
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UK-CCLG and GPOH studies.
Vujanić GM; D'Hooghe E; Graf N; Vokuhl C; Al-Saadi R; Chowdhury T; Pritchard-Jones K; Furtwängler R
Int J Cancer; 2021 Sep; 149(6):1332-1340. PubMed ID: 34109628
[TBL] [Abstract][Full Text] [Related]
5. Near complete resolution of refractory, relapsed, metastatic Wilms' tumour in an adolescent with bevacizumab.
Kumar S; Burney IA; Al-Moundhri MS
J Coll Physicians Surg Pak; 2014 Mar; 24 Suppl 1():S71-2. PubMed ID: 24718015
[TBL] [Abstract][Full Text] [Related]
6. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
[TBL] [Abstract][Full Text] [Related]
8. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Pein F; Pinkerton R; Tournade MF; Brunat-Mentigny M; Levitt G; Margueritte G; Rubie H; Sommelet D; Thyss A; Zücker JM
J Clin Oncol; 1993 Aug; 11(8):1478-81. PubMed ID: 8393095
[TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor: past, present and (possibly) future.
Spreafico F; Bellani FF
Expert Rev Anticancer Ther; 2006 Feb; 6(2):249-58. PubMed ID: 16445377
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy in Wilms' tumour.
Thomas PR
Ann Acad Med Singap; 1996 May; 25(3):425-8. PubMed ID: 8876911
[TBL] [Abstract][Full Text] [Related]
11. Progression of localised Wilms' tumour during preoperative chemotherapy is an independent prognostic factor: a report from the SIOP 93-01 nephroblastoma trial and study.
Ora I; van Tinteren H; Bergeron C; de Kraker J;
Eur J Cancer; 2007 Jan; 43(1):131-6. PubMed ID: 17084075
[TBL] [Abstract][Full Text] [Related]
12. An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour.
Ha TC; Spreafico F; Graf N; Dallorso S; Dome JS; Malogolowkin M; Furtwängler R; Hale JP; Moroz V; Machin D; Pritchard-Jones K
Eur J Cancer; 2013 Jan; 49(1):194-210. PubMed ID: 22959164
[TBL] [Abstract][Full Text] [Related]
13. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.
Metzger ML; Stewart CF; Freeman BB; Billups CA; Hoffer FA; Wu J; Coppes MJ; Grant R; Chintagumpala M; Mullen EA; Alvarado C; Daw NC; Dome JS
J Clin Oncol; 2007 Jul; 25(21):3130-6. PubMed ID: 17634492
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Wilms' tumour. Current recommendations.
Mehta MP; Bastin KT; Wiersma SR
Drugs; 1991 Nov; 42(5):766-80. PubMed ID: 1723373
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumour. Optimal treatment strategies.
Suryanarayan K; Marina N
Drugs; 1998 Oct; 56(4):598-605. PubMed ID: 9806106
[TBL] [Abstract][Full Text] [Related]
16. Results of Wilms' tumour management in two tertiary-care hospitals in Asia.
Sen S; Kadamba P; Al-AbdulAaly M; Mammen KE; Ahmed S
Pediatr Surg Int; 1998 Jan; 13(1):42-4. PubMed ID: 9391203
[TBL] [Abstract][Full Text] [Related]
17. The role of preoperative chemotherapy in the management of Wilms' tumor. The SIOP studies. International Society of Pediatric Oncology.
Graf N; Tournade MF; de Kraker J
Urol Clin North Am; 2000 Aug; 27(3):443-54. PubMed ID: 10985144
[TBL] [Abstract][Full Text] [Related]
18. A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO).
Yau T; Leong CH; Chan WK; Chan JK; Liang RH; Epstein RJ
Cancer Chemother Pharmacol; 2008 Apr; 61(4):717-20. PubMed ID: 17571263
[TBL] [Abstract][Full Text] [Related]
19. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.
Ortiz MV; Ahmed S; Burns M; Henssen AG; Hollmann TJ; MacArthur I; Gunasekera S; Gaewsky L; Bradwin G; Ryan J; Letai A; He Y; Naranjo A; Chi YY; LaQuaglia M; Heaton T; Cifani P; Dome JS; Gadd S; Perlman E; Mullen E; Steen H; Kentsis A
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391345
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
